Home > Animal Health & Nutrition > Veterinary Pharmaceuticals > Cat Vaccines Market

Cat Vaccines Market Trends

Report ID: GMI12323
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Cat Vaccines Market Trends

Increasing pet ownership and rising expenditures on pet health are key trends driving the growth of the market.

According to People's Dispensary for Sick Animals (PDSA), in UK 11 million pet cats are owned by 24% of the adult population, reflecting strong pet ownership rates in 2023. As more people consider cats part of their family, they invest in preventive healthcare to ensure their cats' well-being.
This includes regular vaccines and routine testing to protect against diseases such as Feline Leukemia and Rabies, especially as 90% of cats in Britain have outdoor access, which increases their exposure to pathogens.
Additionally, as per the Humane Society of Huron Valley, spending on cat health is also rising, with owners typically spending between USD 65 – USD 150 annually for vaccines and check-ups, and potentially up to an additional USD 350 for outdoor cats who require more comprehensive care like heartworm, flea/tick preventatives, and additional vaccinations.
This trend of increased spending reflects a greater awareness of pet health needs and a growing willingness to invest in preventive measures. Thus, the demand for comprehensive vaccine options is steadily increasing, thereby fueling the growth of the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global cat vaccines industry was valued at USD 1.1 billion in 2024 and is estimated to grow at a 9.2% CAGR from 2025 to 2034, driven by increasing awareness of animal healthcare and rising pet ownership worldwide.

The modified/attenuated live segment accounted for a 50.5% market share in 2024 due to its high efficacy, robust immune response, and cost-effectiveness, making it a top choice for veterinarians and pet owners.

The U.S. cat vaccines market was valued at USD 378.7 million in 2024, supported by a large pet-owning population and a strong veterinary infrastructure.

Key players in the industry include Bioveta, Boehringer Ingelheim, Durvet, Elanco, Indian Immunologicals, INTAS Animal Health, Merck, Spectra, Virbac, and Zoetis.